Patent application number | Description | Published |
20090067997 | Gas turbine engine with canted pocket and canted knife edge seal - A gas turbine engine is provided with turbine sealing structures including knife edge seals which extend at an angle relative to an axial center line of the engine. Each knife edge seal is associated with a control pocket defined between a radially inner surface and a spaced radially outer surface. The control pockets and their associated knife edge seals create a difficult flow path to prevent leakage into radially inner portions of the turbine section. | 03-12-2009 |
20090232637 | Cooling Air Manifold Splash Plates and Gas Turbines Engine Systems Involving Such Splash Plates - Cooling air manifold splash plates and gas turbine engine systems involving such splash plates are provided. In this regard, a representative cooling air manifold splash plates includes: a base having an aperture; and an air deflector supported by the base, the air deflector being positioned relative to the base to receive, from the aperture, a radial flow of gas turbine engine cooling air, the air deflector being operative to redirect at least some of the air received circumferentially. | 09-17-2009 |
20130017059 | HOLE FOR ROTATING COMPONENT COOLING SYSTEMAANM Wu; Charles C.AACI GlastonburyAAST CTAACO USAAGP Wu; Charles C. Glastonbury CT USAANM McCusker; Kevin N.AACI West HartfordAAST CTAACO USAAGP McCusker; Kevin N. West Hartford CT USAANM Turner; Mark S.AACI HartfordAAST CTAACO USAAGP Turner; Mark S. Hartford CT US - A rotor for a gas turbine engine comprises an annular body and a plurality of holes. The annular body is configured to rotate in a circumferential direction about an axis extending through a center of the annular body. The annular body comprises an outer diameter surface and an inner diameter surface. The plurality of holes extends through the annular body. Each of the holes comprises an elongate profile in the circumferential direction, and a side wall extending between the outer diameter surface and the inner diameter surface. The side wall is slanted in the circumferential direction. | 01-17-2013 |
20130115081 | HIGH SOLIDITY AND LOW ENTRANCE ANGLE IMPELLERS ON TURBINE ROTOR DISK - According to an embodiment disclosed herein, an apparatus for cooling a rotating part having cooling channels therein, the rotating part attaching to a disk rotating about an axis, the disk having a conduit for feeding a cooling fluid to the cooling channel is described. The apparatus has a first impeller rotating with the disk and in register with the conduit and an outer periphery of the disk, the impeller directing the cooling flow to the conduit. | 05-09-2013 |
20160003166 | GAS TURBINE ENGINE TURBINE IMPELLER PRESSURIZATION - A cooling system for a gas turbine engine turbine section includes a rotor supporting a blade having a cooling passage. A disc is secured relative to the rotor and it forms a cavity between the rotor and the disc. A bleed air source is in fluid communication with the cavity. An impeller is arranged in the cavity. The impeller is configured to increase a fluid pressure within the cavity to drive bleed air from the bleed air source and thereby provide a pressurized cooling fluid to the cooling passage. | 01-07-2016 |
20160102568 | POWER TURBINE HEAT SHIELD ARCHITECTURE - A power turbine section for a gas turbine engine includes a heat shield assembly mounted to a bearing support, the heat shield assembly forms an outer diameter directed toward an inner vane platform of the power turbine vane array. | 04-14-2016 |
20160102580 | POWER TURBINE INLET DUCT LIP - A power turbine section for a gas turbine engine includes an inlet duct upstream of a first power turbine vane array, the inlet duct including a lip. | 04-14-2016 |
Patent application number | Description | Published |
20100076177 | Hybrid antibodies - Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs. | 03-25-2010 |
20100285030 | Antibodies to Ox-2/Cd200 and Uses Thereof - This application provides methods and compositions for modulating and/or depleting CD200 positive cells. | 11-11-2010 |
20110021758 | HYBRID ANTIBODIES - Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs. | 01-27-2011 |
20110230646 | HYBRID ANTIBODIES - Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments 5 contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and 10 nonhuman CDRs. | 09-22-2011 |
20120148579 | ANTIBODIES TO OX-2/CD200 AND USES THEREOF - This application provides methods and compositions for modulating and/or depleting CD200 positive cells. | 06-14-2012 |
20130172534 | ANTIBODIES TO OX-2/CD200 AND USES THEREOF - This application provides methods and compositions for modulating and/or depleting CD200 positive cells. | 07-04-2013 |
Patent application number | Description | Published |
20100074891 | Sclerostin and the inhibition of Wnt signaling and bone formation - The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism. | 03-25-2010 |
20100298308 | Compositions and methods for bone formation and remodeling - The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt. | 11-25-2010 |
20110086021 | Sclerostin and the inhibition of WNT signaling and bone formation - The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism. | 04-14-2011 |
20120115787 | Sclerostin and the inhibition of WNT signaling and bone formation - The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism. | 05-10-2012 |
20120178747 | Compositions and methods for bone formation and remodeling - The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt. | 07-12-2012 |
20130172332 | COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING - The present disclosure is directed to methods of identifying a compound that binds to or interacts with a protein receptor involved in bone formation. Specifically, the disclosure is directed to methods of identifying a compound that regulates a Wnt pathway in a cell by binding to or interacting with cavities in proteins such as LRP5, LRP 6 and/or frizzled receptor and interfering with receptor binding to other proteins in a Wnt pathway. The present disclosure is further directed to methods and compositions that comprise an identified compound for treating or preventing a disease in a mammal in which Wnt pathway suppression plays a role. | 07-04-2013 |
Patent application number | Description | Published |
20100041645 | RHO KINASE INHIBITORS - Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma. | 02-18-2010 |
20100273781 | CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula (I): | 10-28-2010 |
20100280028 | CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula (I): | 11-04-2010 |
20120289551 | MINERALOCORTICOID RECEPTOR ANTAGONISTS - Mineralocorticoid receptor antagonists, of which the following is exemplary. | 11-15-2012 |
20130029971 | CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula (I): | 01-31-2013 |
20140357652 | RHO KINASE INHIBITORS - Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds. | 12-04-2014 |
20150297581 | RHO KINASE INHIBITORS - Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds. | 10-22-2015 |
Patent application number | Description | Published |
20120011079 | DERIVING ENTITY-CENTRIC SOLUTION MODELS FROM INDUSTRY REFERENCE PROCESS AND DATA MODELS - A mechanism is provided for forming a business entity model. A selection of business components is received from a business function model to be selected business components. Activities are found in an industry reference model to be selected activities corresponding to selected business components. Based on the selected activities, industry reference model is scoped to be a scoped industry reference model, which includes reducing business process models in the industry reference model to selected business process models corresponding to selected activities, reducing data models in the industry reference model to selected data models corresponding to use cases of selected activities, and reducing service operations in the industry reference model to selected service operations corresponding to the selected activities. Selected activities and scoped industry reference model are customized. Based on a business entity template, selected activities, and scoped industry reference model, business entities are generated to form a business entity model. | 01-12-2012 |
20120297390 | CREATION OF FLEXIBLE WORKFLOWS USING ARTIFACTS - Execution of flexible workflows using artifacts is described. A workflow execution engine is configured to instantiate a process execution (PE) artifact. The PE artifact includes one or more transitions. The workflow execution engine is further configured to execute the one or more transitions and determine if any of the one or more transitions are new or modified. The workflow execution engine is additionally configured to load and execute new or modified transitions, without reinstantiating the PE artifact, responsive to determining that at least one new or modified transitions exist. | 11-22-2012 |
20140053072 | AUTOMATED, CONTROLLED DISTRIBUTION AND EXECUTION OF COMMANDS AND SCRIPTS - Distributed execution of commands and scripts may comprise a script execution manager having access to a library of executable objects comprising at least one or more of commands or scripts or combination of commands and scripts. A script execution console may be operable to present a graphical user interface for selecting an executable object from the library to execute and for selecting one or more managed computers, on which to execute the selected executable object. The script execution console may be further operable to present a dynamically updated collation of results from execution of the selected executable object. One or more script execution agents may be operable to run on the selected respective one or more managed computers and further operable to communicate with the script execution manager. | 02-20-2014 |
20140053073 | AUTOMATED, CONTROLLED DISTRIBUTION AND EXECUTION OF COMMANDS AND SCRIPTS - Distributed execution of commands and scripts may comprise a script execution manager having access to a library of executable objects comprising at least one or more of commands or scripts or combination of commands and scripts. A script execution console may be operable to present a graphical user interface for selecting an executable object from the library to execute and for selecting one or more managed computers, on which to execute the selected executable object. The script execution console may be further operable to present a dynamically updated collation of results from execution of the selected executable object. One or more script execution agents may be operable to run on the selected respective one or more managed computers and further operable to communicate with the script execution manager. | 02-20-2014 |
20140321631 | CONFERENCE CALL AUTHENTICATION UTILIZING PASSCODES PERSONAL TO USERS - A system comprises a plurality of user devices and a conference call bridge connected to the plurality of end user devices via one or more networks. The conference call bridge is configured to connect to a given one of the plurality of user devices, receive a passcode from the given user device, and authenticate the given user device using the passcode. The passcode is personal to the given user. | 10-30-2014 |
20140323085 | CONFERENCE CALL AUTHENTICATION UTILIZING PASSCODES PERSONAL TO USERS - A system comprises a plurality of user devices and a conference call bridge connected to the plurality of end user devices via one or more networks. The conference call bridge is configured to connect to a given one of the plurality of user devices, receive a passcode from the given user device, and authenticate the given user device using the passcode. The passcode is personal to the given user. | 10-30-2014 |
20140358623 | BUSINESS PROCESS MINING USING CROWDSOURCING - A method and system for systematically creating or improving business processes utilizing crowdsourcing. Business process steps and step connection requirements received from a plurality of experts are optimized, ordered and verified. Business process step optimization consists of eliminating invalid or obsolete business process steps received, identifying and eliminating duplicate business process steps received, and selecting most efficient business process steps. Business process steps are ordered based on the connection requirements received. Created or improved business processes are verified by a plurality of experts utilizing crowdsourcing. | 12-04-2014 |
20160048685 | PROTECTED SHELL FOR RISK VALIDATION - On a computer system, a shell is invoked, through which a plurality of commands and/or scripts can be executed. Individual ones of the plurality of commands and/or scripts are validated. Given individual ones of the plurality of commands and/or scripts, for which the validation is successful, are executed via the shell. | 02-18-2016 |
20160080575 | CONFERENCE CALL AUTHENTICATION UTILIZING PASSCODES PERSONAL TO USERS - A system comprises a plurality of user devices and a conference call bridge connected to the plurality of end user devices via one or more networks. The conference call bridge is configured to connect to a given one of the plurality of user devices, receive a passcode from the given user device, and authenticate the given user device using the passcode. The passcode is personal to the given user. | 03-17-2016 |
Patent application number | Description | Published |
20080215397 | SYSTEM AND MECHANISM TO CREATE AUTONOMIC BUSINESS SOLUTIONS - Automomic business processes management solutions have capabilities to adapt themselves to changes in the business environment. These autonomic business solutions are built by wiring together autonomic solution components called BPbots (Business Process robots). BPbots are granular solution components representing an aspect of a business process. In general, BPbots consist of two parts, an execution module and a managerial module. The execution module represents the standard, non-autonomic solution component, such as a standard process flow model describing the long-running flow or business adapter describing the communication of the solution with service providers (such as applications). The managerial module is responsible for the autonomic behavior of the BPbot. The managerial component has the ability to monitor the execution module, analyze the performance, plan new, more appropriate execution patterns and change the behavior of the execution module according to the new plan. | 09-04-2008 |
20090187552 | System and Methods for Generating Data Analysis Queries from Modeling Constructs - A method for automatically generating data analysis queries from at least one modeling construct includes selecting a preconfigured template identifying at least one metric or dimension; retrieving dashboard model data comprising the preconfigured template; filtering to the dashboard model data using at least one user-specific access control; and automatically generating a query for at least one database. | 07-23-2009 |
20150200959 | MANAGING RISK IN MULTI-NODE AUTOMATION OF ENDPOINT MANAGEMENT - It is determined whether a user is authorized to carry out a management operation on a plurality of information technology assets in parallel, based on a role of the user and at least one characteristic of the management operation. A risk level of the management operation, and at least one characteristic of the plurality of information technology assets, are both determined. Based on the risk level and the at least one characteristic of the plurality of information technology assets, an execution pattern for the management operation is specified. In at least some cases, the management operation is carried out on the plurality of information technology assets in parallel, in accordance with the execution pattern. | 07-16-2015 |
20150294250 | BUILDING CONFIDENCE OF SYSTEM ADMINISTRATOR IN PRODUCTIVITY TOOLS AND INCREMENTAL EXPANSION OF ADOPTION - A system management tool, with a risk assessment mode enabled, is executed within an execution infrastructure on a management computer system, to manage a target computer system in a production situation. When the execution of the tool reaches a risk segment which raises risk for the target system, a user is informed of at least one action to be executed in the risk segment. If the user agrees, the tool is allowed to execute in an automatic mode until an end of the risk segment is reached. Feedback is obtained from the user regarding safety of the risk segment; and the steps are repeated for a plurality of additional risk segments until the tool is deemed safe for all of the risk segments, after which the tool is transitioned from the risk assessment mode to an automatic mode of operation. | 10-15-2015 |
Patent application number | Description | Published |
20080235046 | METHOD AND SYSTEM FOR CONNECTING BUSINESSES THROUGH COMMON INTERESTS - A method of connecting businesses through common interests can include storing business profiles comprising business attributes in an online business registry. Responsive to a query from an inquiring business, the online business registry can be searched to locate at least one business having a business profile including at least one business attribute corresponding to the query. At least one communications link between the inquiring business and the located business can be established according to at least one business attribute of the business profile of the located business. | 09-25-2008 |
20110219375 | ENHANCED WORK-FLOW MODEL CAPABLE OF HANDLING EXCEPTIONS - A system and method for augmenting a work-flow model to handle all expected and unexpected exceptions during run-time. The system includes an Exception Handling Knowledge Base (EHKB), a Work-flow Manager for managing the execution of the work-flow model and automatically adding exception transitions from the EHKB to the model except those forbidden, and a Work-flow Monitor for monitoring the model execution. The Monitor generating alerts to a business manager when the exceptions are encountered. At build-time, a process analyst could define a process schema in a Process Schema Repository, specify a forbidden exception or modify a schema to handle an exception based on guidance from the EHKB. At run-time, a user may initiate a forbidden exception with approval from the business manager. | 09-08-2011 |
20160036817 | Protected Graphical User Interface for Role-Based Application and Data Access - Methods, systems, and computer program products for a protected graphical user interface for role-based application and data access are provided herein. A method for controlling access on an endpoint device to at least a portion of an application includes obtaining a default configuration indicating whether one or more widget functions associated with the application are enabled in a graphical user interface; modifying one or more of the widget functions in the default configuration to a disabled status in the graphical user interface based on a privilege configuration; determining if one or more user click events generated using the graphical user interface are associated with a widget function having the disabled status; and preventing the user click events having the disabled status from being provided to an operating system for further processing, wherein at least one of the steps is carried out by a computing device. | 02-04-2016 |
Patent application number | Description | Published |
20080312185 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES - Disclosed are methods of treating cancer by administration of compounds according to formula (I): | 12-18-2008 |
20090275611 | Compounds Which Modulate The CB2 Receptor - Compounds are provided which bind to and are agonist, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R | 11-05-2009 |
20100009964 | Compounds Which Modulate The CB2 Receptor - Compounds of formula (I) are disclosed. Compounds according to the and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 01-14-2010 |
20100076029 | Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 03-25-2010 |
20100081644 | Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 04-01-2010 |
20100261708 | Diazepane Compounds Which Modulate The CB2 Receptor - Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 10-14-2010 |
20110136869 | Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 06-09-2011 |
20110301161 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 12-08-2011 |
20110312932 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 12-22-2011 |
20110312944 | Heterocyclic Compounds Which Modulate The CB2 Receptor - Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 12-22-2011 |
20120010184 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 01-12-2012 |
20120142666 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor - Compounds of the formula (I), (II) and (III) which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 06-07-2012 |
20120142677 | Pyrrolidine Compounds Which Modulate The CB2 Receptor - Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. (I) | 06-07-2012 |
20120214787 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 08-23-2012 |
20120220561 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compound of formula (I): | 08-30-2012 |
20120245162 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 09-27-2012 |
20120295896 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I) and (IA): | 11-22-2012 |
20130030022 | Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 01-31-2013 |
20130196967 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compound of formula (I): | 08-01-2013 |
20150291607 | COMPOUNDS AS MODULATORS OF ROR GAMMA - The present invention encompasses compounds of the formula (I) | 10-15-2015 |
20160075706 | COMPOUNDS AS MODULATORS OF ROR GAMMA - The present invention encompasses compounds of the formula (I) | 03-17-2016 |